70 respondents participated with a 90% completion rate. 98% reported caring for primarily pediatric patients. 97% reported board certification/eligibility in child neurology, 84% in epilepsy, and 48% in clinical neurophysiology. 98% trained in the US. A majority were 5-10 or 10-20 years out of training. 

20% of respondents preferred corticosteroids as first line, while 65% preferred benzodiazepines. When utilizing corticosteroids, 65% preferred daily dosing, 10% preferred pulsed dosing, and 24% preferred a combined daily/pulsed regimen. The preferred daily corticosteroid was prednisone (94%). There was major variability in treatment duration (<1 to 6 months) and taper duration (2 to >12 weeks). Most taper regimens were non-standardized. IV methylprednisolone was the most preferred pulsed corticosteroid (50%), with treatment ranging from <1 to 12 months. All respondents used EEG to monitor treatment response, performed <4 to 12 weeks after treatment initiation. 

Few SEs were surveilled using a formal protocol. Possibility of SEs was the most impactful barrier to corticosteroid use. Respondents reported being more comfortable with managing SEs than their practices reflected.